[{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Meropenem And Vaborbactam","moa":"Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Meropenem And Vaborbactam","moa":"Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"}]

Find Clinical Drug Pipeline Developments & Deals for Meropenem And Vaborbactam

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPOR Europe 2025
                          Not Confirmed
                          ISPOR Europe 2025
                          Not Confirmed

                          Details : Vabomere is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bacterial Infections.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          February 22, 2016

                          Lead Product(s) : Meropenem And Vaborbactam

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Department of Health and Human Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ISPOR Europe 2025
                          Not Confirmed
                          ISPOR Europe 2025
                          Not Confirmed

                          Details : Vabomere is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 20, 2014

                          Lead Product(s) : Meropenem And Vaborbactam

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Department of Health and Human Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank